Polatuzumab Vedotin Clinical Trials
12 recruitingDrug
Phase 28Phase 15
Showing 1–12 of 12 trials
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled75 locationsNCT05283720
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 1
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+3 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 2
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Phase 2
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Chronic Lymphocytic LeukemiaRichter's Transformation
Christine Ryan70 enrolled5 locationsNCT06043674
Recruiting
Phase 1Phase 2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington35 enrolled1 locationNCT05455697
Recruiting
Phase 2
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Chronic Lymphocytic LeukemiaRichter Syndrome
Weill Medical College of Cornell University20 enrolled4 locationsNCT04679012
Recruiting
Phase 2
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular Lymphoma+3 more
City of Hope Medical Center41 enrolled2 locationsNCT06453044
Recruiting
Phase 1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
CNS Lymphoma
Juan P. Alderuccio, MD20 enrolled1 locationNCT06730542
Recruiting
Phase 2
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Refractory or Relapsed Diffuse Large B Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT06554600